Physician profile
Casandra Mateo
NPI 1477567691
$10,582.08
in general payments reported to CMS, 2019-2025
49 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $280 · 2021: $1,341 · 2022: $1,734 · 2023: $1,740 · 2024: $2,672 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,970.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,300.78 | 2021-2025 | |
| Ucb, INC. | $1,689.36 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Mdd US Operations, LLC | $724.53 | 2022-2025 | Apokyn, Apokyn |
| Pfizer INC. | $536.06 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $454.10 | 2019-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $389.59 | 2020-2021 | |
| Sk Life Science, INC. | $384.85 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $340.35 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $331.06 | 2022 | |
| Eisai INC. | $294.17 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $255.57 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.82 | 2024-2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $209.07 | 2020-2025 | |
| Amgen INC. | $200.89 | 2021-2023 | Aimovig |
| Lundbeck LLC | $186.33 | 2023-2025 | Rexulti, Vyepti |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $178.27 | 2019 | |
| Acadia Pharmaceuticals INC | $172.22 | 2020-2022 | |
| Kyowa Kirin, INC. | $165.76 | 2021-2024 | Nourianz |
| Argenx US, INC. | $159.57 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $153.28 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $139.71 | 2021-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $131.17 | 2019-2022 | |
| Neurelis, INC. | $104.25 | 2023-2025 | Valtoco |
| Biogen, INC. | $93.85 | 2020-2025 | Leqembi, Skyclarys |
| Axsome Therapeutics, INC. | $92.39 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $84.73 | 2023-2024 | Austedo Xr |
| Akcea Therapeutics, INC. | $53.34 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $48.25 | 2025 | Inbrija, Xeomin |
| Octapharma USA, INC. | $40.73 | 2022-2023 | Panzyga |
| Acorda Therapeutics, INC | $33.74 | 2020-2021 | |
| Abbott Laboratories | $33.62 | 2021 | |
| Avion Pharmaceuticals | $30.89 | 2023 | Dhivy |
| Boston Scientific Corporation | $29.69 | 2025 | Watchman Flx |
| Revance Therapeutics, INC. | $29.25 | 2024 | Daxxify |
| Livanova USA, INC. | $27.56 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $27.44 | 2020-2022 | |
| Microtransponder, INC. | $24.65 | 2025 | |
| Vanda Pharmaceuticals INC. | $23.00 | 2025 | Ponvory |
| Genentech USA, INC. | $19.59 | 2025 | Ocrevus Zunovo |
| Arbor Pharmaceuticals, INC. | $18.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.92 | 2022 | |
| Greenwich Biosciences, INC. | $16.64 | 2021 | |
| Impel Pharmaceuticals INC. | $16.60 | 2023 | Trudhesa |
| Celgene Corporation | $15.43 | 2025 | Zeposia |
| Sobi, INC | $14.62 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.41 | 2025 | Crexont |
| Hyperfine Operations, INC. | $13.87 | 2024 | Swoop |
| Emd Serono, INC. | $12.52 | 2021 | |
| Aucta Pharmaceuticals, INC. | $6.64 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casandra Mateo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.